BioReperia gains international recognition!

BioReperia has recently joined an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

 

We are delighted to announce that our portfolio company BioReperia has taken part in an international consortium of 10 partners under the umbrella of the H2020-MSCA-RISE program.

RISE program connects organizations from the academic and non-academic sectors (in particular SMEs). By linking research and personnel, and sharing expertise and ideas between the innovation research field to the market field, RISE facilitates international and multisectoral cooperation. The scheme promotes a shared research and innovation culture that embraces and recognizes creativity and entrepreneurship.

This grant will help BioReperia to progress and advance their technology (zebrafish ZTX-platforms) towards IVD-precision medicine and drug discovery. The program offers assistance thought collaborative research and the development of innovation for the project. The objective is to share knowledge via international and intersectoral mobility, based on research and innovation staff allocation with an in-built return mechanism.

BioReperia’s innovative technology will shed light on immune-oncology, specifically how dysregulation in cysteine leukotriene signaling contributes to cancer development.

 

About BioReperia

BioReperia AB is a privately-owned contract research organization (CRO) founded in September 2015 based on technology developed at Linköping University in Sweden. Their technology is used to accelerate drug discovery and individual test treatments on specific patients in clinical trials. They are active as a CRO in the European market for drug discovery in academic institutions and pharmaceutical companies. BioReperia AG was incorporated at HEMEX’s incubator on december 2019 to focus on the development of IVD to fight against different types of cancers. More info at BioReperia.

 

 About Hemex

HEMEX is a private investment and consulting company headquartered close to the Basel global life sciences hub. Our primary focus is to bring innovative drugs, medical devices, and in-vitro diagnostics to the market. We specialized in supporting early-stage start-ups, offering tailored solutions to accelerate projects into successful and sustainable businesses. If you would like to know more about our work, you can find more information at HEMEX.

The Weaker Sex?

Portraits of successful women in science

Hemex is particularly inspired by the hard-working women who push boundaries to create innovative healthcare solutions. Dedicated and powerful female leaders enrich the diversity of our Swiss start-up portfolio. Today, we would like to introduce five remarkable female role models to you.

Becoming a successful entrepreneur / leader is not easy, especially for women. Two common challenges female leaders face in the academic and scientific world are sometimes referred to as the “glass ceiling” (the invisible barrier that keeps women from rising) and the “leaky pipeline” phenomenon (the way that women disappear from some career pathways).

The process of building a new company from scratch is challenging, yet incredibly rewarding when dreams materialize, and new discoveries improve the lives of people around the world. Research shows that companies that embrace team gender diversity are stronger and more efficient at tackling external and internal challenges. Therefore, we have decided to dedicate this post to our fast-growing list of impressive female leaders in our portfolio companies.

 

Iselin Frøybu

Iselin is Co-founder and COO at EMOVO CARE. She is a hardware engineer who studied Mechanical Engineering at Penn State University and has a Master’s degree from EPFL. Iselin turned into a business developer with a passion for developing meaningful technologies. She says that the question is no longer whether we can make something, but rather whether we should. She also likes to fight stereotypes and entropy. Iselin is an inspiring woman, who has played a crucial role in the company’s success. Her work never ceases to amaze us. With Emovo Care, Iselin is on a mission to significantly improve quality of life for stroke survivors.

 

Özge Karakas

Özge is Co-Founder and COO at Hi-D IMAGING. She is an experienced scientist, entrepreneur, and a postdoctoral researcher at ETH Zurich. Özge has over 10 years of experience in thermodynamics and fluid dynamic models. On top of this, she has completed a minor degree in Computer Science and Engineering. Özge has been instrumental in the company’s creation, writing the business plan and managing company finances.

 


Ronja Bruhn

Ronja is CEO and Co-Founder of STIMIT. She is a medical engineer with an MBA in Innovation & Entrepreneurship. With 12 years of experience in R&D industry projects and an EMEA product launch, Ronja has impressive experience when it comes to bringing healthcare products to market. Her hard work has demonstrated that STIMIT provides added clinical benefits to patients. With STIMIT, Ronja works on a noninvasive solution for patients lacking natural breathing function. STIMIT’s vision is to empower sedated ICU patients to breathe, creating natural breath instead of pumping air into the lungs.

 

Danuta Cichocka

Danuta is the CEO and Co-Founder of RESISTELL. She is a microbiologist passionately driven by life science, innovation, and self-development. She finished her PhD at the UFZ Leipzig, completed the Executive MBA program at EPFL, and obtained a CAS in Management of Biotech, Medtech & Pharma Ventures. Her key strength is being able to bridge the gap between research and business. Her ability to translate a complex problem into manageable challenges is admirable. Being able to not only see the big picture but knowing how to communicate it is a valuable strength that we truly appreciate at Hemex. With Resistell, Danuta works on the world’s fastest antibiogram to save lives by finding the right antibiotic in time and combat antibiotic resistance.

 

Marija Plodinec

Marija is CEO and Co-Founder of ARTIDIS. She believes in the potential of their technology to transform a cancer patient’s journey (and so do we at HEMEX). Marija studied physics at the University of Zagreb and completed her doctorate from the Maurice Müller Institute at the Biozentrum of the University of Basel. She is also a member of several international organizations and a Senior Principal Scientist at the University Hospital Basel. She is an energic source of inspiration in the field of physical sciences in oncology. At Artidis, Marija is dedicated to developing a rapid diagnostic technique to detect cancer.

 

Still think women are the “Weaker Sex”? Think again and embrace diversity – as we do here at Hemex!

How Animal Health Innovation Enabled a Rapid and Reliable SARS-CoV-2 Diagnostic Test Kit

In the battle of fighting against COVID-19, a rapid test is crucial to understand the spread of the pandemic.

The Swiss start-up LiVET that originally developed diagnostic tests for respiratory diseases in horses has accelerated their platforms to detect COVID-19 in human samples, establishing a newly incorporated company ender diagnostics ag. Undeniably, ender is a fascinating example of how health developments can be transferred from animal health technology into human health. ender’s isothermal technology utilizes a single temperature for all the steps providing a dramatic decrease of detection time when comparing to the gold standard polymerase-chain-reaction (PCR). In addition, its 30-minute turnover platform can support a relatively small sample size, no need for waiting for a large sample size in a batch. Thus, it is flexible and efficient to operate in laboratories.

Besides the currently sold CE-marked detection kit ender LAB, the company is developing its new outstanding platforms, ender MAS and ender MOBILE, which provide much simplified steps for the sample handling and for point-of-care purpose.

As of 25 June, the cost of all coronavirus tests, including coronavirus and antibody tests, will be covered by the Swiss federal government, implying that people would be more willing to get themselves tested (source: The Federal Council). The Federal Office of Public Health (FOPH) has encouraged people to participate in prevention efforts by installing the SwissCovid app, a proximity tracing system to help in contact tracing and informing people who have spent a certain time with someone who tested positive for coronavirus.

Hand holding mobile with geoHealthApp for COVID-19 tracking

A similar app has been already launched in Switzerland in April by GeoHealthApp, a german start-up supported by HEMEX.

In an estimated 8,000 tests per day carried out in Switzerland, the need for tests is still increasing (source: thelocal.ch). A prediction model of Prof. Dirk Mohr at ETH Zurich suggests that the second pandemic wave would develop more slowly but potentially more deadly (source: Swissinfo). The good news is that it would not overload the Swiss healthcare capacity and we could better prepare in testing and tracing the population. There is no doubt that start-ups such as ender diagnostics play a pivotal role in this battle of COVID-19.

In summary, with the increased availability of advanced testing kits and tracing apps, we can now better monitor the current pandemic status in Switzerland and respond rapidly in order to prevent catastrophic local outbreaks.

HEMEX supports LiVET, ender diagnostics, and GeoHealthApp with clinical, regulatory and market access services.

For more information, see Swissinfo.ch.

Welcome Hi-D Imaging!

Medical technology diagnostics of heart concept.Medicine doctor and stethoscope working with Ui heart and diagnostics analysis medical treatment.

We are delighted to welcome Hi-D Imaging AG to our growing list of portfolio companies and are pleased to support them as a strategic clinical and regulatory development partner.

Hi-D Imaging AG, an ETH Spin-off medtech company founded in July 2019, aims to revolutionize the cardiovascular sector by making personalized aortic heart valve replacement therapy a reality. The diverse team of engineers and cardiologists of Hi-D applies high precision fluid dynamics analysis and machine learning algorithms to develop the world’s first AI-based pre-operational planning platform. The platform assesses full hemodynamics in patient-specific anatomies and is offered as “Software as a Service” (SaaS).  

Hi-D’s goal is to increase the patient’s quality of life and optimize the design of next-generation heart valves. Hi-D builds a bridge between clinical teams and heart valve manufacturers to provide the best treatment for patients with cardiovascular diseases. Hi-D is planning 3 clinical proof of concept trials in Europe and in the US.

The start-ups will share more information on their journey at the HEMEX pitching event on June 5th.

The HEMEX PORTFOLIO contains a selection of the most promising Swiss and European life science start-ups. Headquartered close to the Basel global life sciences hub, our main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business.